Product Images Ramipril

Each capsule contains 10 mg of the drug Ramipril, USP and comes in a package size of 100 capsules identified by the NDC number 0054-0109-25. The usual dosage and other complete information about the drug are available in the Ramipril B package insert and prescribing information. The drug should be kept away from children and stored in a tight, light-resistant and child-resistant container. The recommended storage temperature is between 20°C to 25°C. The drug is distributed by Hikma Pharmaceuticals USA, Inc. in Berkeley Heights, NJ.*

Ramipril is a medication that comes in capsule form containing 1.25 mg of ramipril, USP. The dosage instructions are provided in the package insert, and the drug should be kept out of reach of children. It must be stored in a tightly-sealed, light-resistant, and child-resistant container as per the regulations. Hikma Pharmaceuticals USA Inc. is the distributor of the drug.*

This is a description of a medication called Ramipril Capsules, USP. Each capsule contains 2.5 mg of ramipril, USP, and the usual dosage can be found in the package insert. It is important to keep this medication and all drugs out of reach of children and dispense in a tight and light-resistant container. The medication should be stored at a temperature of 20° to 25°C (68 to 77°F), and the NDC number is 0054-0107-25. This medication is distributed by Hikma Pharmaceuticals USA Inc. in Berkeley Heights, NJ 07922.*

Each capsule contains 5mg of Ramipril, USP. It comes in a pack of 100 capsules, each having an NDC of 0054-0108-25. The usual dosage information can be found in the Ram |pr|| Package Insert. This drug should be kept out of children's reach and stored in a tight and light-resistant container according to USP standards. The containers should also be child-resistant as defined in the USP/NF guidelines. Store the drug at a temperature of 20° to 25°C (68° to 77°F). This drug is distributed by Hikma Pharmaceuticals USA Inc. located in Berkeley Heights, NJ.*

This is a graph depicting the proportion of patients over 1000 days of follow-up. The proportion starts at 0.00 and goes up to 0.20. The graph shows the use of ramipril, with a significant result denoted by P=0.0001.*